The first dose of Heplisav news along with a good quarterly report was not good enough to make DVAX a rocket ship today. Buying interests were simply overwhelmed by the profit-taking selling pressure --- a big institutional holder, BVF, has been selling at every rally for cash needs since last March and hence keeping a lid on the pps upon every good news. All the shares I bought in AH yesterday and PM today are severely under water. Even with significant news, the pps cannot make any meaningful strike until this determined seller is done selling. Any good trader may make good money with this stock but I am very lousy at trading. I will simply hold for the big fat payday yet to come. Yesterday's baby-step news on Heplisav improves the company's fundamentals even more significantly. I am wiring cash tomorrow to my broker to either add DVAX should it dip or initiate ORGAJ.
Improved fundamentals: with yesterday's news in the bag, the FDA clinical hold on Heplisav is expected to be lifted by the end of September. This may lead to co-development/marketing partnership with a big pharma, which will surely consist of upfront cash payment, sharing of clinical trial costs and revenues. The status of Heplisav in Europe and Asia is yet to be updated. New developments in the pipeline.